<DOC>
	<DOCNO>NCT02632019</DOCNO>
	<brief_summary>Objectives : The purpose study evaluate safety prognosis dendritic cell-precision T cell neo-antigen treatment advance biliary tract malignant tumor . Methods : This study design novel therapy use dendritic cell-precision multiple antigen T cell . 40 patient enrol . They randomly divide gemcitabine group dendritic cell-precision T cell neo-antigen combined gemcitabine group . Gemcitabine treatment perform week total six time . Dendritic cell-precision T cell neo-antigen combined gemcitabine treatment : Gemcitabine : week total six time 60 day prior start draw blood . Dendritic cell-precision T cell neo-antigen : per 3 week total three period . The mail clinical indicator Progression-Free-Survival Overall Survival .</brief_summary>
	<brief_title>Immunotherapy Using Precision T Cells Specific Personalized Neo-antigen Treatment Advanced Malignant Tumor Biliary Tract</brief_title>
	<detailed_description>A total 40 patient may enrol period 1-2 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Age 18~65 year old , male female ; 2 . Life expectancy ＞ 6 month ; 3 . Eastern Cooperative Oncology Group ( ECOG ) score : 02 ; 4 . Laboratory examination : ① white blood cell ≥ 3 x 109/L . blood platelet count ≥ 60 x 109/L ; hemoglobin ≥85g/L ; ② total bilirubin ≤100 mol/L ; aminopherase less five time normal ; ③ serum creatinine less 1.5 time normal ; 5 . Signed informed consent ; 6 . Patients fertility willing use contraceptive method . 1 . Expected Overall survival ＜ 6 month ; 2.Other serious disease : heart , lung , kidney , digestive , nervous , mental disorder , immune regulatory disease , metabolic disease , infectious disease , Etc.3.serum creatinine &gt; 2.5mg/dL ; Serum Glutamic Oxaloacetic Transaminase ( SGOT ) &gt; 5 time normal ; total bilirubin &gt; 100μmol/L ; 4.Other drug , biological , chemotherapy radiation therapy use within 1 month ; 5 . Without sign Informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>advanced biliary tract malignant tumor</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>precision T cell neo-antigen</keyword>
</DOC>